SCHEMBL2567685

SCHEMBL2567685

O=S(=O)(Nc1ccc(C(F)(F)F)cc1)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 1/20 0.71
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
ALDH1A1 P00352 2/20 0.67
PKM P14618 1/20 0.67
AR P10275 2/20 0.66
KEAP1 Q14145 2/20 0.66
IL1RN P18510 1/20 0.66
ERAP1 Q9NZ08 1/20 0.66
PPARG P37231 1/20 0.61
PGR P06401 2/20 0.61
NR3C1 P04150 1/20 0.61
ESR2 Q92731 1/20 0.61
FFAR4 Q5NUL3 1/20 0.59
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
CA12 O43570 1/20 0.59
CA9 Q16790 1/20 0.59
POLB P06746 1/20 0.58
MAPT P10636 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572845 0.93 KMT2A (0.67) NR1H3MEN1KMT2AALDH1A1PKM
SCHEMBL14601685 0.91 MEN1 (0.65) NR1H3MEN1KMT2AALDH1A1AR
SCHEMBL12010912 0.89 NR1H3 (0.68) NR1H3MEN1KMT2AALDH1A1AR
SCHEMBL12010881 0.85 MEN1 (0.68) NR1H3MEN1KMT2AALDH1A1AR
SCHEMBL810795 0.84 KMT2A (0.91) MEN1KMT2AALDH1A1PKMKEAP1
SCHEMBL7577535 0.84 CA1 (0.65) MEN1KMT2AALDH1A1PKMAR
SCHEMBL2415124 0.83 NR1H3 (1.00) NR1H3MEN1KMT2AALDH1A1PKM
SCHEMBL7571036 0.83 CES1 (0.73) MEN1KMT2AALDH1A1ARPGR
SCHEMBL18031173 0.83 UQCRB (0.71) NR1H3MEN1KMT2AARERAP1
SCHEMBL4573249 0.83 KMT2A (0.71) MEN1KMT2AALDH1A1ARKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382191-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS Abbott Laboratories, Inc. (US) 2011-11-02 EP claimed
CN-108822002-B Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves 中南大学 2020-05-05 CN disclosed
CN-108822002-A A kind of method of ultrasonic wave added synthesis N- aryl sulfonic acid amides 中南大学 2018-11-16 CN disclosed
US-8175860-B2 Method of inhibiting the growth of Helicobacter pylori NATIONAL TSING HUA UNIVERSITY (TW) 2012-05-08 US disclosed
EP-2382191-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS Abbott Laboratories, Inc. (US) 2011-11-02 EP disclosed
US-20100305152-A1 METHOD OF INHIBITING THE GROWTH OF HELICOBACTER PYLORI NATIONAL TSING HUA UNIVERSITY (TW) 2010-12-02 US disclosed
EP-1519932-A1 BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY Cyclacel Limited (GB) 2005-04-06 EP disclosed
WO-2004005278-A1 BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY CYCLACEL LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305152-A1 METHOD OF INHIBITING THE GROWTH OF HELICOBACTER PYLORI HPD, HAAO, HK1 NR1H3 3143/4885MEN1 2935/4885KMT2A 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.